Mid-term Outcomes of First MTP Arthroplasty With Primus™ FGT Implant.

September 12, 2016 updated by: Stryker Trauma GmbH

A Post-Market Observational Study to Evaluate Safety and Performance of Primus™ FGT Implant at a Minimum of 5 Years Follow-up

Foot silicone implants suffer from bad reputation on the market, due to poor results obtained with the first generations of implants. Allergies to silicone, infections due to silicone and implants breakage used to be common with previous generations of silicone implants. Publications relative to those implants showed that the survival rates after 5 years of follow-up were unsatisfactory.

Since 1998, Tornier has been selling a new generation of silicone implants made of Ultrasil™. The use of this new material in its manufacturing process together with its innovative geometry, make the Primus™ FGT a much more resistant, anatomic and long lasting implant.

The main objective of this study is to evaluate the clinical outcomes of the implantation of Primus™ FGT implant in great toe arthroplasty. The study will capture long term outcomes in terms of functional metrics from documented clinical data. Other objectives are to evaluate the outcomes in terms of radiological evaluation and of safety during all the follow-up.

Study Overview

Detailed Description

This is an observational post-marketing surveillance study, performed by 1 (one) investigator in 1 (one) Italian site.

  • Preoperative and peroperative data were collected retrospectively.
  • Postoperative data (minimum 5 years follow-up or until implant revision) were collected prospectively.

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Vicenza, Italy, 36100
        • Casa Di Cura Villa Berica

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study has included all patients who had had a Primus™ FGT implantation.

Description

Inclusion Criteria:

  • patient has had a Primus™ FGT implantation for one of the following indications: hallux limitus, hallux rigidus, hallux abducto valgus associated with severe arthritis, unstable or painful joint from previous surgery on the great toe,
  • patient having all necessary clinical and radiographical data available.,
  • patient has been informed about this scientific study and has provided their Consent to participate.

Exclusion Criteria:

  • patient does not have clinical and radiographic follow-up data available.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AOFAS Hallux-MTP-IP Score - Overall
Time Frame: mean 6.9 years follow-up (range 5.2 - 9.5)
AOFAS (American Orthopedic Foot and Ankle Society) Hallux-MTP-IP (Hallux-Meta-Tarso-Phalangeal-Inter-Phalangeal) score is composed of 3 sub-scores : (i) Pain score is ranging from 0 to 40 points ; Function score is ranging from 0 to 45 points ; Alignment is ranging from 0 to 15 points. The AOFAS total score is then ranging from 0 to 100 points. A result over 80 points is considered "good", below 20 points as "bad".
mean 6.9 years follow-up (range 5.2 - 9.5)
AOFAS Hallux-MTP-IP - PAIN Score
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Pain is a sub-score of the AOFAS Hallux-MTP-IP score and is measured on a scale of 40 points - the higher value represents a minimal pain.
mean follow-up of 6.9 years (range, 5.2 - 9.5)
Pain at Passive Motion of MTP1
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Number of patients reporting pain at passive motion of MTP1 at preoperative and postoperative visits.
mean follow-up of 6.9 years (range, 5.2 - 9.5)
Pain at Pressure of MTP1
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Number of patients reporting pain at pressure of MTP1 at preoperative and postoperative visits.
mean follow-up of 6.9 years (range, 5.2 - 9.5)
Walking Perimeter
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Subjective evaluation by the patients of their walking perimeter, postoperatively versus preoperatively. Patient had to choose among 3 variables : "improved", "same", "worsened".
mean follow-up of 6.9 years (range, 5.2 - 9.5)
Pain During Walking
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Subjective evaluation by patients about pain during walking, postoperatively versus preoperatively. Patients had to choose among 4 variables : "disappeared", "less", same", "greater".
mean follow-up of 6.9 years (range, 5.2 - 9.5)
Pain at Rest
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
Subjective evaluation of patients about ther pain at rest, postoperatively versus preoperatively. Patients had to choose among 4 variables : "disappeared", "less", "same, "greater".
mean follow-up of 6.9 years (range, 5.2 - 9.5)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Osteolysis
Time Frame: mean 6.9 years (range, 5.5 - 9.5)
Osteolysis evaluation was described as : absent or present. Radiological evaluations were done from available frontal and lateral view X-rays.
mean 6.9 years (range, 5.5 - 9.5)
Bone Resorption
Time Frame: mean 6.9 years (range, 5.5 - 9.5)
Bone resorption evaluation was described as : absent or present. Radiological evaluations were performed from available frontal and lateral view X-rays.
mean 6.9 years (range, 5.5 - 9.5)
Survival of the Implant.
Time Frame: mean follow-up of 6.9 years (range, 5.2 - 9.5)
The survival of the implant is evaluated according to the number of implant revisions or of reoperations, whatever the reason.
mean follow-up of 6.9 years (range, 5.2 - 9.5)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stefano FIESCHI, MD, Casa di Cura Villa Berica - Vicenza - Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2013

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

January 19, 2015

First Submitted That Met QC Criteria

January 26, 2015

First Posted (Estimate)

January 30, 2015

Study Record Updates

Last Update Posted (Estimate)

October 31, 2016

Last Update Submitted That Met QC Criteria

September 12, 2016

Last Verified

May 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

3
Subscribe